Top-News

ELEVATE INC News

Aktie
WKN:  ISIN:  US2862171046 US-Symbol:  ELEV
Keine aktuellen Kursdaten verfügbar
Depot/Watchlist
Dieses Wertpapier ist nicht mehr handelbar.
Marktkapitalisierung *
-
Streubesitz
-
KGV
-
Index-Zuordnung
-

ELEVATE INC News

12.06.25 - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KNW, ELEV, CRKN on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KNW, ELEV, CRKN on Behalf of Shareholders PR Newswire
09.06.25 - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FLS, KNW, ELEV, CRKN on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FLS, KNW, ELEV, CRKN on Behalf of Shareholders PR Newswire
09.06.25 - PR Newswire
Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right
Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right PR Newswire
15.05.25 - PR Newswire
Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates PR Newswire
25.04.25 - PR Newswire
Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025
Elevation Oncology Presents Preclinical Proof-​of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025 PR Newswire
25.03.25 - PR Newswire
Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025
Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025 PR Newswire
20.03.25 - PR Newswire
Elevation Oncology to Discontinue Development of EO-3021; Advancing EO-1022, While Evaluating Strategic Options
Elevation Oncology to Discontinue Development of EO-3021; Advancing EO-1022, While Evaluating Strategic Options PR Newswire
06.03.25 - PR Newswire
Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Achievements
Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Achievements PR Newswire
25.02.25 - PR Newswire
Elevation Oncology to Participate in Upcoming Investor Conferences
Elevation Oncology to Participate in Upcoming Investor Conferences PR Newswire
13.01.25 - PR Newswire
Elevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming Milestones
Elevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming Milestones PR Newswire
12.12.24 - PR Newswire
Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors
Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors PR Newswire

Newssuche

Videos

newspaper
05.12.25 +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »